Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Biocon Limited ( (IN:BIOCON) ).
Biocon Biologics Ltd, a subsidiary of Biocon Limited, has received FDA approval for Kirsty™, the first and only interchangeable rapid-acting Insulin Aspart in the United States. This approval marks a significant expansion of Biocon Biologics’ diabetes portfolio, complementing its existing product, Semglee®. The introduction of Kirsty™ aims to enhance accessibility and affordability of insulin, offering more treatment options for diabetes patients. With diabetes affecting 38.4 million people in the U.S., this approval positions Biocon Biologics as a key player in addressing unmet needs in diabetes care, reinforcing its commitment to scientific excellence and patient-centric innovation.
More about Biocon Limited
Biocon Limited is a global leader in biosimilars and insulin production, recognized among the top three global players for recombinant human insulin and Insulin Glargine. The company offers a broad portfolio of basal, mixed, and rapid-acting insulins, providing over 9.2 billion doses globally. Biocon Biologics, a subsidiary of Biocon Ltd., has achieved several industry firsts, including the approval of biosimilar products like Trastuzumab, Ogivri®, Fulphila™, and Semglee® in the United States. The company serves over 5.8 million patients annually with a comprehensive portfolio of biosimilar products across multiple therapies.
Average Trading Volume: 146,859
Current Market Cap: 498.5B INR
Find detailed analytics on BIOCON stock on TipRanks’ Stock Analysis page.